7.08
-1.26%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Ausun Pharmaceutical Co
Its shares trade on Shanghai under the ticker 603229.SS. It has been listed since 9 May 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥792.8m and net income of CN¥130.6m. At that date it held total assets of CN¥3.09bn and shareholders' equity of CN¥2.27bn.
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the manufacture, sale, research and development of pharmaceutical intermediates and raw materials. The company is headquartered in Taizhou, Zhejiang. The company went IPO on 2017-05-09. The firm's main products include bimatoprost, latanoprost, latanoprostene bunod, entecavir, selectfluor and other intermediates. The firm is also involved in the provision of customized production, as well as research and development services to customers through its subsidiaries.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 May 2017
- Employees
- 1,129
- Website
- ausunpharm.com ↗
Leadership
Pay as last reported
- Mr. Zhiguo ZhengChairman of the Board, General Manager, since 2014CN¥853,900
- Ms. Dingmin ZhuChief Financial OfficerCN¥158,100
- Mr. Huadong ZhangDirector, Deputy General Manager, since 2014CN¥378,000
- Mr. Kai GaoDeputy General ManagerCN¥628,300
- Mr. Jiguo SongDeputy General Manager
- Ms. Yu ZhongDeputy General ManagerCN¥519,200
- Mr. Xiaochen YingSecretary of the BoardCN¥58,300
- Mr. Fei ChenDirector
- Mr. Yu LiuDirectorCN¥324,200
- Ms. Shilan ZhengDirectorCN¥263,900
- Ms. Hemin ZhuDirector
- Mr. Mingmin LuoIndependent DirectorCN¥70,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhejiang Ausun Pharmaceutical's bimatoprost and latanoprost are key products in the ophthalmic pharmaceutical market.
- The company's R&D services through subsidiaries support customized production for global clients.
- 1,129 employees ensure robust manufacturing and research capabilities in Taizhou.
Weaknesses
- Limited product diversity beyond bimatoprost and latanoprost in the pharmaceutical intermediates segment.
- Dependence on specific intermediates like entecavir may limit market adaptability.
- No mention of international expansion beyond current operations in China.
Opportunities
- Growing demand for ophthalmic drugs like latanoprostene bunod in global markets.
- Customized production services can attract more international pharmaceutical firms.
- Expansion into new pharmaceutical intermediates could leverage R&D expertise.
Threats
- Competition from Chinese pharmaceutical manufacturers in the intermediates market.
- Regulatory changes in China could impact production and sales of intermediates.
- Overreliance on specific products like selectfluor may pose supply chain risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.